Neurol. praxi. 2021;22(6):496-500 | DOI: 10.36290/neu.2021.096

Treatment of secondary progressive multiple sclerosis with siponimod and a case report

MUDr. Veronika Tichá, Ph.D.
Neurologická klinika a Centrum klinických neurověd, 1. LF UK a VFN v Praze

Siponimod is a selective modulator of S1P1 and S1P5 subtypes of sphingosin-1 phosphate receptors with dual mechanism of action. It exerts the anti-inflammatory effect by blocking the egress of lymphocytes from the lymph nodes and the neuroprotective effect due to direct interaction with glial a neuronal brain cells. EXPAND clinical trial showed the positive effect of siponimod on the risk of disability progression, number of relapses, cognitive performance and activity and progression on MRI compared to placebo. Siponimod is indicated for the treatment of secondary progressive Multiple Sclerosis with disease progression and clinical or MRI activity, in adults. The dose of siponimod must be reduced in case of decreased CYP2C9 enzyme activity due to genetic polymorphism.

Keywords: multiple sclerosis, secondary progressive, siponimod, oral treatment, CYP2C9.

Received: December 1, 2021; Revised: December 1, 2021; Accepted: December 4, 2021; Prepublished online: December 4, 2021; Published: December 9, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tichá V. Treatment of secondary progressive multiple sclerosis with siponimod and a case report. Neurol. praxi. 2021;22(6):496-500. doi: 10.36290/neu.2021.096.
Download citation

References

  1. Behrangi N, Fischbach F, Kipp M. Mechanism of Siponimod: Anti-Inflammatory andNeuroprotective Mode of Action. Cells 2019; 8(1): 24. doi: 10.3390/cells8010024 Go to original source... Go to PubMed...
  2. Goodman AD, Anadani N, Gerwitz L. Siponimod in the treatment of multiple sclerosis. Expert Opin Investig Drugs. 2019 Dec; 28(12): 1051-1057. DOI: 10.1080/13543784.2019.1676725 Go to original source... Go to PubMed...
  3. Informace o základní úhradě LP Mayzent [online]. Dostupné z URL: https://www.sukl.cz/modules/medication/detail.php?code=0238786&tab=prices.
  4. Kappos L, Bar-Or A, Cree BA, For RJ, Giovannoni G, Gold R, Vermerck P, Arnold DL, Arnould S, Scherz T, Wolf CH, Wallstrőm E, Dahlke F, EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 2018; 391 (10127): 1263-11273. doi: 10.1016/S0140-6736 (18) 30475-6. Go to original source... Go to PubMed...
  5. Kipp M. Does Siponimod Exert Direct Effects in the Central Nervous System? Cells 2020; 9(8): 1771. doi: 10.3390/cells9081771. Go to original source... Go to PubMed...
  6. Mayzent. Souhrn údajů o přípravku [online]. Dostupné z URL: https://www.ema.europa.eu/en/documents/product-information/mayzent-epar-product-information_cs.pdf.
  7. O'Sullivan C, Schubart A, Mir AK, Dev KK. The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures. J Neuroinflammation 2016; 13: 31. doi: 10.1186/s12974-016-0494-x. Go to original source... Go to PubMed...
  8. Scalfari A, Neuhaus A, Daumner M, Murraro PA, Ebers GC. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry 2014; 85(1): 67-75. doi: 10.1136/jnnp-2012-304333. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.